Intervention Review

Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients

  1. Zhen Guo2,
  2. Zongying Wu3,
  3. Yang Wang4

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 23 APR 2008

Assessed as up-to-date: 18 FEB 2008

DOI: 10.1002/14651858.CD005443.pub2


How to Cite

Guo Z, Wu Z, Wang Y. Antacids for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD005443. DOI: 10.1002/14651858.CD005443.pub2.

Author Information

  1. 2

    West China Hospital, Digestive Diseases Department, Chengdu, Sichuan, China

  2. 3

    Sichuan University, Digestive Disease Department of West China Hospital, Chengdu, Sichuan, China

  3. 4

    Chongqing Medical University, School of Public Health, Chongqing, China

*Jinlin Yang, Department of Gastroenterology, West China Hospital, Sichuan University, South Renmin Road, Chengdu, Sichuan Province, 610041, China. mouse-577@163.com. wuzl_basehouse@163.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 23 APR 2008

SEARCH

 

Abstract

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Background

Ruptured gastroesophageal varices are the most severe and frequent cause of gastrointestinal bleeding in cirrhotic patients, leading to death in 5% to 8% of patients during the first 48 hours and oesophagogastric varices account for 60% to 80% of first bleeding in patients with portal hypertension. Antacids are often used for emergency treatment of bleeding oesophageal varices in patients with cirrhosis of the liver.

Objectives

To evaluate the beneficial and harmful effects of antacids for preventing oesophagogastric bleeding and rebleeding.

Search methods

We planned to identify relevant randomised clinical trials by searching The Cochrane Hepato-Biliary Group Controlled Trials Register (June 2007), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 2, 2007), MEDLINE (1950 to June 2007), EMBASE (Excerpta Medica Database) (1980 to June 2007), and the Science Citation Index Expanded (SCI-EXPANDED) (1945 to June 2007). Additional randomised trials were sought from the reference lists of the trials found and reviews identified by the electronic searches.

Selection criteria

We planned to include randomised clinical trials.

Data collection and analysis

We planned to summarise data using Cochrane Collaboration methodologies.

Main results

We could not find any randomised clinical trials on antacids for preventing oesophagogastric variceal bleeding and bleeding in cirrhotic patients.

Authors' conclusions

It is not possible to determine whether antacids are beneficial or harmful for preventing oesophagogastric variceal bleeding and rebleeding in cirrhotic patients since randomised clinical trials investigating this question are lacking.

 

Plain language summary

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

Evidence to establish the beneficial and harmful effects of antacids for preventing oesophagogastric variceal bleeding and bleeding in cirrhotic patients is lacking

Randomised trials with antacids for preventing oesophagogastric variceal bleeding and bleeding in cirrhotic patients could not be found. Valid evidence for or against the use of antacids for preventing oesophagogastric variceal bleeding and bleeding in cirrhotic patients is lacking.

 

摘要

  1. Top of page
  2. Abstract
  3. Plain language summary
  4. 摘要

背景

制酸劑用於預防肝硬化患者合併食道靜脈曲張出血及再次出血所扮演的角色

食道靜脈曲張出血是肝硬化患者腸胃道出血最嚴重且常見的原因,它造成了5∼8%的患者在前48小時內死亡。約有60 ∼ 80%的門靜脈高壓患者的第一次的腸胃道出血是由食道靜脈曲張所引起。制酸劑時常用在肝硬化患者合併食道靜脈曲張出血的緊急治療。

目標

評估制酸劑用於預防食道靜脈曲張出血或再出血的益處與害處。

搜尋策略

我們搜尋了以下的資料庫,找出當中相關的隨機臨床試驗: The Cochrane HepatoBiliary Group Controlled Trials Register (2007年6月), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 2, 2007), MEDLINE (1950年至2007年6 月), EMBASE (Excerpta Medica Database) (1980至 2007年6月), and the Science Citation Index Expanded (SCIEXPANDED) (1945至2007年6月).我們利用電子搜尋來搜尋參考文獻及其所列的原始臨床試驗資料。

選擇標準

我們計劃把隨機臨床試驗包含進來。

資料收集與分析

我們計劃使用考科藍共同研究方法學來歸納這些資料。

主要結論

我們無法找到任何制酸劑用於預防肝硬化患者合併食道靜脈曲張出血或再出血的相關隨機臨床試驗資料。

作者結論

既然沒有相關的隨機臨床試驗資料,制酸劑用於預防肝硬化患者合併食道靜脈曲張出血或再出血的益處與害處就無法評估。

翻譯人

本摘要由臺北榮民總醫院陳邦彥翻譯。

此翻譯計畫由臺灣國家衛生研究院(National Health Research Institutes, Taiwan)統籌。

總結

臨床上制酸劑用於預防肝硬化患者合併食道靜脈曲張出血或再出血的益處與害處的證據不足。找不到制酸劑用於預防肝硬化患者合併食道靜脈曲張出血或再出血的相關隨機臨床試驗資料。目前缺乏合理的證據來贊成或反對使用制酸劑來預防肝硬化患者合併食道靜脈曲張出血或再出血。